CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
复制标题
DOI：
10.1158/1078-0432.ccr-09-2329
复制
发表时间：
2010-06-01
影响因子：
11.5
通讯作者：
Fricker, Simon P.
中科院分区：
文献类型：
--
作者：
Teicher, Beverly A.;Fricker, Simon P.
趋化因子是一种小的促炎化学引诱细胞因子，与特定的G蛋白偶联的七跨膜受体结合，是细胞运输和粘附的主要调节因子。趋化因子CXCL 12 [基质细胞衍生因子-1（SDF-1）]主要与CXC受体4（CXCR 4; CD 184）结合。CXCL 12与CXCR 4的结合通过几种不同的途径诱导细胞内信号传导，引发与趋化性、细胞存活和/或增殖、细胞内钙增加和基因转录相关的信号。CXCR 4在多种细胞类型上表达，包括淋巴细胞、造血干细胞、内皮和上皮细胞以及癌细胞。CXCL 12/CXCR 4轴参与肿瘤进展、血管生成、转移和存活。该途径是可以阻断CXCL 12/CXCR 4相互作用或抑制下游细胞内信号传导的治疗剂的靶标。临床癌症研究; 16（11）; 2927-31。(C)2010年AACR。
Chemokines, small proinflammatory chemoattractant cytokines that bind to specific G-protein-coupled seven-span transmembrane receptors, are major regulators of cell trafficking and adhesion. The chemokine CXCL12 [stromal cell-derived factor-1 (SDF-1)] binds primarily to CXC receptor 4 (CXCR4; CD184). The binding of CXCL12 to CXCR4 induces intracellular signaling through several divergent pathways initiating signals related to chemotaxis, cell survival and/or proliferation, increase in intracellular calcium, and gene transcription. CXCR4 is expressed on multiple cell types including lymphocytes, hematopoietic stem cells, endothelial and epithelial cells, and cancer cells. The CXCL12/CXCR4 axis is involved in tumor progression, angiogenesis, metastasis, and survival. This pathway is a target for therapeutics that can block the CXCL12/CXCR4 interaction or inhibit downstream intracellular signaling. Clin Cancer Res; 16(11); 2927-31. (C) 2010 AACR.